Stay updated on Efficacy of AMONDYS 45, EXONDYS 51, VYONDYS 53 Clinical Trial

Sign up to get notified when there's something new on the Efficacy of AMONDYS 45, EXONDYS 51, VYONDYS 53 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Efficacy of AMONDYS 45, EXONDYS 51, VYONDYS 53 Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the efficacy and safety evaluation of AMONDYS 45, EXONDYS 51, VYONDYS 53 for the treatment of boys with Duchenne Muscular Dystrophy carrying eligible DMD duplications.
    Difference
    0.1%
    Check dated 2024-06-06T14:29:16.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to a detailed description of eligibility criteria for clinical research. The new criteria specify that participants must be males with Duchenne Muscular Dystrophy (DMD) having specific exon duplications and meet certain health conditions.
    Difference
    12%
    Check dated 2024-05-22T20:30:07.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:28:03.000Z thumbnail image

Stay in the know with updates to Efficacy of AMONDYS 45, EXONDYS 51, VYONDYS 53 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Efficacy of AMONDYS 45, EXONDYS 51, VYONDYS 53 Clinical Trial page.